APA (7th ed.) Citation

Chng, W. J., Goldschmidt, H., & Dimopoulos, M. A. (2017). Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia, 31(6), . https://doi.org/10.1038/leu.2016.390

Chicago Style (17th ed.) Citation

Chng, Wee Joo, Hartmut Goldschmidt, and Meletios A. Dimopoulos. "Carfilzomib-dexamethasone Vs Bortezomib-dexamethasone in Relapsed or Refractory Multiple Myeloma by Cytogenetic Risk in the Phase 3 Study ENDEAVOR." Leukemia 31, no. 6 (2017). https://doi.org/10.1038/leu.2016.390.

MLA (9th ed.) Citation

Chng, Wee Joo, et al. "Carfilzomib-dexamethasone Vs Bortezomib-dexamethasone in Relapsed or Refractory Multiple Myeloma by Cytogenetic Risk in the Phase 3 Study ENDEAVOR." Leukemia, vol. 31, no. 6, 2017, https://doi.org/10.1038/leu.2016.390.